Frontpage Hero

Because we care, we need to act

Statement from the CEO

Building for balance and growth

"Sobi is delivering on a solid strategy for growth. Building on our strength in Haemophilia, we aim to grow the business with a broader Specialty Care portfolio to ensure long-term sustainability and strength and make a real difference for people with rare diseases."

Press releases

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for anakinra for the treatment of Still’s disease. The opinion is now referred to the European Commission...

02/23/2018 - 15:55

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the fourth quarter and full-year 2017. Total revenues for the full-year amounted to SEK 6,511 M, an increase of 25 per cent. Revenues for the quarter were SEK 1,875 M, an increase of 45 per cent. Product sales for the full...

02/22/2018 - 08:00

On 22 February, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the fourth quarter and full year 2017.

Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 14:00...

02/13/2018 - 09:00

Swedish Orphan Biovitrum AB (publ) (Sobi™) will present new evidence at the upcoming 11th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), in Madrid, Spain, 7-9 February 2018. These data mark the company´s long-term commitment to elevate haemophilia...

02/07/2018 - 12:30
Contact us

Sobi Head Office
+46 8 697 20 00
Tomtebodavägen 23A
SE-112 76 Stockholm, Sweden